继发性甲状旁腺机能亢进的诊疗进展

doi:10.6040/j.issn.1673-3770.1.2016.10

摘要/Abstract

摘要： 继发性甲状旁腺机能亢进(SHPT)是慢性肾功能不全(CKD)代谢紊乱所致的一类常见并发症,发病率逐年升高,临床表现为甲状旁腺激素(PTH)升高,伴有钙磷代谢紊乱、骨痛等症状。CKD继发甲状旁腺机能亢进的发病机制,除了熟知的因素(包括血钙血磷、维生素D及其受体、钙敏感受体等)以外,还涉及分子和细胞机制,如肽酰脯氨酰顺反异构酶1(Pin1)、抗衰老蛋白Klotho、成纤维细胞生长因子23等。目前治疗SHPT的主要方法有药物治疗、外科手术治疗和介入治疗,对手术治疗的术前定位和手术术式进行综述。

关键词: 继发性甲状旁腺功能亢进, 定位, 治疗

Abstract: Secondary hyperparathyroidism(SHPT)is a common complication of metabolic disorders in chronic kidney disease(CKD)patients. The Incidence of SHPT has increased with the passing years and the clinical manifestations are increased parathyroid hormone level, calcium-phosphorus metabolic disorders and bone pain, et al. In addition to the familiar factors, such as serum calcium and phosphorus, vitamin D and its receptor, calcium-sensing receptors, the mechanism for CKD-SHPT also includes the molecular and cellular mechanism, such as peptidyl-prolyl cis-trans isomerase 1(Pin1), Klotho protein and fibroblast growth factor-23(FGF23). Nowadays, the therapeutic strategy is mainly focused on medication, surgery and interventional therapy. This review will also introduce the pre-operation localization methods and surgical methods. Its critical to choose the suitable surgical methods for SHPT treatment.

Key words: Localization, Secondary hyperparathyroidism, Treatment

中图分类号:

R582.2

陈隽,王家东. 继发性甲状旁腺机能亢进的诊疗进展[J]. 山东大学耳鼻喉眼学报, 2016, 30(2): 36-39.

CHEN Jun, WANG Jiadong. Treatment advance of secondary hyperthyroidism.[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2016, 30(2): 36-39.

参考文献

[1] Slatopolsky E, Bown A, Dusso A. Role of phosphorus in pathogenesis of secondary hyperparathyroidism[J]. Am J Kidney Dis, 2001, 37:S54-S57.
[2] 孙鲁英,王梅,杨莉. 终末期肾脏病患者钙磷代谢及甲状旁腺激素水平的临床分析[J]. 北京大学学报(医学版), 2005, 37(2):36-39. SNU Luying, WANG Mei, YANG Li. Study of calcium-phosphorous metabolism and intact parathyroid hormone levels in end stage renal disease patients[J]. J Peking Univ(Health Sci), 2005, 37(2):36-39.
[3] 贾彦诺,高志华,徐然东,等. 慢性肾衰竭继发性甲状旁腺功能亢进的相关因素分析及治疗[J]. 中国老年学杂志, 2015, 35(11):3182-3184.
[4] Nechama M, Uchida T, Mor Yosef-Levi I, et al. The peptidylprolyl isomerase Pin1 determines parathyroid hommne mRNA levels and stability in rat models of secondary hyperparathyroidism[J]. J Clin Invest, 2009, 119(10):3102-3114.
[5] 赵玉,张丽丽,曹平, 等.PIN1基因启动子区-667C>T多态性与慢性肾脏病伴继发性甲状旁腺功能亢进的相关性[J].肾脏病与透析肾移植杂志,2013,22(6):513-519. ZHAO Yu, ZHANG Lili, CAO Ping, et al. Correlation of PIN1 gene promoter region-667C > T polymorphism with secondary hyperparathyroidism of chronic kidney disease[J]. Chin J Nephrol Dialysis Transplant, 2013, 22(6):513-519.
[6] Komaba H, Fukagawa M. FGF23-Parathyroid interaction:implications in chronic kidney disease[J]. Kidney Int, 2010, 77(4):292-298.
[7] Kuro-o M. Klotho in health and disease[J]. Curr Opin Nephrol Hypertens, 2012, 21(4):362 -368.
[8] 冯嘉麟, 周秦毅, 陈隽, 等. 继发性甲状旁腺功能亢进外科治疗的疗效分析[J]. 中华耳鼻咽喉头颈外科杂志, 2015, 50(8):661-667. FENG Jialin, ZHOU Qinyi, CHEN Jun, et al. Therapeutic evaluation of surgical procedure in treatment of secondary hyperparathyroidism[J]. Chin J Otorhinolaryngol Head Neck Surg, 2015, 50(8):661-667.
[9] Parfrey P S, Drüeke T B, Block G A, et al. The effects of cinacalcet in older and younger patients on hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events(EVOLVE)trial[J]. Clin J Am Soc Nephrol, 2015, 10(5):791-799.
[10] Perry C M, Plosker G L. Sevelamer carbonate: a review in hyperphosphataemia in adults with chronic kidney disease[J]. Drugs, 2014, 74(7):771-792.
[11] Hutchison A J, Barnett M E, Krause R, et al. Long- term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment[J]. Nephron Clin Pract, 2008, 110(1):c15-23.
[12] Lund R J, Andress D L, Amdahl M, et al. Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients[J]. Am J Nephrol, 2010, 31(2):165-170.
[13] Jun Chen, Jia-dong Wang. Radioguided parathyroidectomy in patients with secondary hyperparathyroidism due to chronic renal failure[J]. Nuclear Medicine Communications, 2014, 35:391-397.
[14] Johnson N A, Carty S E, Tublin M E. Parathyroid imaging[J]. Radiol Clin North Am, 2011, 49(3):489-509.
[15] 张庆,张青.甲状旁腺显像存在的问题及进展[J]. 江西医药,2006,41(11):920-921.
[16] 周建平,李昱骥,董明, 等. 原发性甲状旁腺功能亢进的定位诊断[J].中华普通外科杂志,2005,14(9):227-228. ZHOU Jianping, LI Yuji, DONG Ming, et al.Localizing diagnosis of primary hyperparathyroidism[J]. Chin J Gen Surgery, 2005, 14(9):227-228.
[17] Chen H, Sippel R S, Schaefer S. The effectiveness of radioguided parathyroidectomy in patients with negative technetium Tc 99m-sestamibi scan[J]. Arch Surg, 2009, 144(7):643-648.
[18] Harris R, Ryu H, Vu T, et al. Modern approach to surgical intervention of the thyroid and parathyroid glands[J]. Semin Ultrasound CT MR, 2012, 3(2):115-122.
[19] Richards M L, Wormuth J, Bingener J, et al. Parathyroidectomy in secondary hyperparathyroidism: Is there an optimal operative management?[J]. Surgery, 2006, 139(2):174-180.
[20] Shih M L, Duh Q Y, Hsieh C B, et al. Total parathyroidectomy without autotransplantation for secondary hyperparathyroidism[J]. World J Surg, 2009, 33(2):248-254.
[21] Chen J, Zhou Q Y, Wang J D. Comparison between subtotal parathyroidectomy and total parathyroidectomy with autotransplantation for secondary hyperparathyroidism in patients with chronic renal failure: a meta-analysis[J]. Horm Metab Res, 2015, 47(9):643-651.
[22] Agha A, Loss M, Schlitt H J, et al. Recurrence of secondary hyperparathyroidism in patients after total parathyroidectomy with autotransplantation: technical and therapeutic aspects[J]. Eur Arch Otorhinolaryngol, 2012, 269(5):1519-1525.
[23] Goldstein R E, Billheimer D, Martin W H, et al. Sestamibi scanning and minimally invasive radioguided parathyroidectomy without intraoperative parathyroid hormone measurement[J]. Ann Surg, 2003, 237(5):722-730.
[24] Rubello D, Giannini S, Martini C, et al. Minimally invasive radio-guided parathyroidectomy[J]. Biomed Pharmacother, 2006, 60(3):134-138.
[25] Cayo A, Chen H. Radioguided reoperative parathyroidectomy for persistent primary hyperparathyroidism[J]. Clin Nucl Med, 2008, 33(10):668-670.
[26] Fujii T, Yajima R, Yamaguchi S, et al. Could the eZ-SCOPE AN gamma camera replace intraoperative measurement of iPTH for PHPT?[J]. Inter Surgery, 2012, 97(2):99-103.
[27] Gencoglu E A, Aktas A. The efficacy of low and high dose(99m)Tc-MIBI protocols for intraoperative identification of hyperplastic parathyroid glands in secondary hyperparathyroidism[J]. Rev Esp Med Nucl Imagen Mol, 2014, 33(4):210-214.
[28] 张凌. 继发性甲状旁腺功能亢进的治疗策略[J]. 中华肾病研究电子杂志, 2015, 4(3):5-9. ZHANG Ling. Strategy for the treatment of secondary hyperparathyroidism[J]. Chin J Kid Dis Invest(Electr Ver), 2015, 4(3):5-9.

相关文章 15

[1]	方璐, 雷玉丹, 王华. 环孢素滴眼液联合玻璃酸钠滴眼液治疗干眼临床效果的Meta分析[J]. 山东大学耳鼻喉眼学报, 2026, 40(2): 65-73.
[2]	雷玉丹,方璐,陈健,彭昌福. 托珠单抗治疗激素抵抗或不耐受的中重度甲状腺相关性眼病临床疗效的Meta分析[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 54-67.
[3]	朱明琼,李征,刘茹,田涛,彭婧利,吕倩怡,谭华霞. 基于OCT/OCTA的AI筛查系统在抗VEGF治疗糖尿病性黄斑水肿患者效果评价中的应用[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 68-73.
[4]	卢朝阳, 翟兆雪, 王慧康, 邵丽婷, 张宇. 新冠肺炎治疗引发糖尿病酮症酸中毒合并鼻眶脑型毛霉菌病1例并文献复习[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 90-94.
[5]	顾敏,陆美萍. 纳米药物输送系统在变应性鼻炎过敏原免疫治疗中的应用进展[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 106-111.
[6]	刘一洁,卢秀珍,吴秋欣. 外泌体在眼病发病机制和诊疗中的研究进展[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 135-141.
[7]	刘玉柱,陈尧,苑铁君,李春森,李波. 喉纤维肉瘤1例并相关文献复习[J]. 山东大学耳鼻喉眼学报, 2025, 39(6): 133-137.
[8]	韩鑫宇,陈钢钢,李莹,周丽媛,杨捷,吴佳鑫,李育军. 双侧前庭病的非药物治疗研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(6): 154-159.
[9]	王晓杰,张明君,宋哲莹,崔丽梅,宋西成. 山奈酚抗癌的作用机制及研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(6): 168-178.
[10]	许雪萌,樊磊,喻望博,蒋芝月,潘晨,黄泳芹. 奥马珠单抗联合特异性免疫治疗变应性鼻炎疗效的Meta分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 26-33.
[11]	刘玉柱,苑铁君,李波. 会厌原发神经内分泌癌1例并文献复习[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 97-100.
[12]	张婷,王美兰,高映勤. 白细胞介素35在变应性鼻炎中的研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 139-147.
[13]	邱前辉,肖旭平,杨钦泰,叶菁,邓泽义,王德生,谭国林,蒋卫红,卢永田,唐隽,石照辉,邓晓聪,刘遗斌,王跃武,段传志,杜德坤,白小欣,陈文伙,莫立根,蔡楚伟,曾鹏,何旭英,杨一梅,赵洲洋,陈健龙,赵充,林志雄,李先明,李曙平,陈冬平,陈勇,黄莹,陈春燕,韩非,黄理金,瞿申红. 鼻咽癌治疗后并发颈动脉爆裂综合征的临床处理专家共识[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 1-18.
[14]	朱瑞楷,吴家荣,孙芳,谢楚波,邱前辉. 基于计算机断层扫描血管造影术评估鼻咽癌放疗后引起颈内动脉狭窄状况及其影响因素的研究[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 77-84.
[15]	石金莲,李建兴,黄幼生,林铭轩,刘灵云,卢永田. 喉部炎性肌纤维母细胞瘤的研究现状与诊疗进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(4): 186-192.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed